{"database": "lobbying", "table": "lobbying_activities", "rows": [[623354, "29063c95-802c-4309-8fc6-96b3769330ed", "Q2", "CAPITOL HILL CONSULTING GROUP", 72053, "ELI LILLY AND COMPANY", 2008, "second_quarter", "PHA", "General Pharmaceutical issues pertaining to Eli Lilly and Company, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug importation", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2008-07-09T10:51:32-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["623354"], "units": {}, "query_ms": 0.3413039958104491, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}